Nathalie Nicolaiew Selected Research

Docetaxel (Taxotere)

11/2010

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nathalie Nicolaiew Research Topics

Disease

9	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 08/2007
4	Neoplasms (Cancer) 05/2015 - 02/2010
2	Carcinoma (Carcinomatosis) 05/2015 - 08/2007
1	Prostatic Intraepithelial Neoplasia 03/2009
1	Carcinogenesis 01/2009

Drug/Important Bio-Agent (IBA)

3	Prostate-Specific Antigen (Semenogelase)IBA 05/2015 - 03/2009
2	Biomarkers (Surrogate Marker)IBA 05/2015 - 11/2010
2	Androgen Receptors (Androgen Receptor)IBA 07/2013 - 01/2009
2	Estrogens (Estrogen)FDA Link 01/2009 - 08/2007
1	Neuropilin-1IBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 05/2015
1	Kazal Pancreatic Trypsin InhibitorIBA 05/2015
1	AndrogensIBA 07/2013
1	LigandsIBA 07/2013
1	AntigensIBA 03/2011
1	taxaneIBA 11/2010
1	Docetaxel (Taxotere)FDA Link 11/2010
1	TubulinIBA 11/2010
1	SteroidsIBA 01/2009
1	Hormones (Hormone)IBA 01/2009
1	Finasteride (Propecia)FDA LinkGeneric 10/2007
1	EnzymesIBA 10/2007
1	Aromatase (CYP19)IBA 08/2007
1	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 08/2007

Therapy/Procedure

2	Castration 07/2013 - 11/2010
2	Therapeutics 07/2013 - 11/2010
1	Aftercare (After-Treatment) 11/2010
1	Drug Therapy (Chemotherapy) 11/2010
1	Prostatectomy (Retropubic Prostatectomy) 11/2010
1	Chemoprevention 10/2007